Joe Biden beats President Donald Trump in three polls released last week. What was surprising is that Biden was able to pull off the feat despite the recent resurgence in Trump’s popularity as his administration confronts the coronavirus outbreak in the U.S.
Joe Biden posted a two-point lead over Donald Trump in an ABC News/Washington Post poll. Biden got 49 percent over Trump’s 47 percent based on results released on Sunday, according to Politico.
Biden also bested Trump in a Fox News survey among registered voters. Biden raked in 49 points against Trump’s 40 percent based on the results of Fox News’ survey, which was released last week.
Biden also led by 3 points in a polled conducted by Monmouth University. The results revealed that Biden got 48 percent against Trump’s 45 percent.
According to the publication, the results of the three polls show a consistent pattern. Donald Trump has improved his approval rating but it might not translate to a vote for his second term. “The polls suggest a slightly larger-than-usual slice of Democratic-leaning and independent voters are telling pollsters they now approve of the job Trump is doing as president — but support for giving him a second term lags behind among these same voters,” Politico wrote.
Trump’s approval rating reached a new high based on recent polls. The POTUS has an average approval rating of 47 percent, the highest since he became the President, NPR reported. The figure also represents a three-point increase over the last two weeks.
A Gallup poll revealed that 60 percent of American adults approve of how Trump is handling the coronavirus pandemic. Meanwhile, 51 percent of Fox News’ respondents approved of his handling of the health crisis. Meanwhile, both Reuters/Ipsos and Economist/YouGov polls revealed that 49 percent approved of his actions.
“No, I think that we've handled it really well,” Trump said on Monday. “The American public thinks that we've handled it well if you look at polling data.”
However, an expert said that the bounce to his popularity is minimal. “We're seeing although his numbers have inched up, it's still roughly in his zone of support,” Marist College Institute for Public Opinion director Lee Miringoff said. “Look, he's not getting the rally-around-the-president [effect] that presidents in crisis have gotten.”


Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition
Vanda Pharmaceuticals (VNDA) Stock Soars After FDA Approves BYSANTI for Bipolar I and Schizophrenia
Iran War Fallout: How Sri Lanka, Pakistan, and Egypt Are Struggling With Rising Energy Costs
Spain's Sanchez Visits China to Deepen Trade Ties Amid U.S. Tensions
BCA Research Warns U.S.-Iran Ceasefire Could Collapse, Maintains Cautious Equity Outlook
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine
Hungary's Orban Loses Power as Magyar Wins in Landslide; U.S. Reactions Divided
FDA Warns Novo Nordisk Over Misleading Ozempic Ad Claims
U.S. Blockades Strait of Hormuz Amid Escalating Iran Tensions
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors
Peru Presidential Election 2026: Keiko Fujimori Takes Early Lead in First-Round Vote
Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval 



